Literature DB >> 14633661

Complex effects of Ras proto-oncogenes in tumorigenesis.

Roberto Diaz1, Lluis Lopez-Barcons, Daniel Ahn, Antonio Garcia-Espana, Andrew Yoon, Jeremy Matthews, Ramon Mangues, Roman Perez-Soler, Angel Pellicer.   

Abstract

Ras proteins have been found mutated in about one-third of human tumors. In vitro, Ras has been shown to regulate distinct and contradictory effects, such as cellular proliferation and apoptosis. Nonetheless, the effects that the wild-type protein elicits in tumorigenesis are poorly understood. Depending on the type of tissue, Ras proto-oncogenes appear to either promote or inhibit the tumor phenotype. In this report, we treated wild-type and N-ras knockout mice with 3-methylcholanthrene (MCA) to induce fibrosarcomas and found that MCA is more carcinogenic in wild-type mice than in knockout mice. After injecting different doses of a tumorigenic cell line, the wild-type mice exhibited a shorter latency of tumor development than the knockouts, indicating that there are N-ras-dependent differences in the stromal cells. Likewise, we have analyzed B-cell lymphomas induced by either N-methylnitrosourea or by the N-ras oncogene in mice that over-express the N-ras proto-oncogene and found that the over-expression of wild-type N-ras is able to increase the incidence of these lymphomas. Considered together, our results indicate that Ras proto-oncogenes can enhance or inhibit the malignant phenotype in vivo in different systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633661     DOI: 10.1093/carcin/bgh026

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Wild type N-ras displays anti-malignant properties, in part by downregulating decorin.

Authors:  Marta Benet; Robin Yates Dulman; Raffi Suzme; Eleazar Vega-Saenz de Miera; Martha E Vega; Thuy Nguyen; Jiri Zavadil; Angel Pellicer
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

2.  Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis.

Authors:  Corinne E Camalier; Matthew R Young; Gerd Bobe; Christine M Perella; Nancy H Colburn; George R Beck
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

3.  Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews.

Authors:  Jian-Jia Su; Ke-Chen Ban; Yuan Li; Liu-Liang Qin; Hui-Yun Wang; Chun Yang; Chao Ou; Xiao-Xian Duan; Young-Lk Lee; Rui-Qi Yang
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 4.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

5.  Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.

Authors:  Steffan Vartanian; Carolyn Bentley; Matthew J Brauer; Li Li; Senji Shirasawa; Takehiko Sasazuki; Jung-Sik Kim; Pete Haverty; Eric Stawiski; Zora Modrusan; Todd Waldman; David Stokoe
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

6.  CircPVT1 attenuates negative regulation of NRAS by let-7 and drives cancer cells towards oncogenicity.

Authors:  Joshua Miguel C Danac; Reynaldo L Garcia
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

7.  Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia.

Authors:  Alejandro M Hortal; Clara L Oeste; Claudia Cifuentes; Miguel Alcoceba; Isabel Fernández-Pisonero; Laura Clavaín; Rut Tercero; Pilar Mendoza; Verónica Domínguez; Marta García-Flores; Belén Pintado; David Abia; Carmen García-Macías; Almudena Navarro-Bailón; Xosé R Bustelo; Marcos González; Balbino Alarcón
Journal:  Mol Cancer       Date:  2022-02-04       Impact factor: 27.401

Review 8.  Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors.

Authors:  Nastaran Khazamipour; Nader Al-Nakouzi; Htoo Zarni Oo; Maj Ørum-Madsen; Anne Steino; Poul H Sorensen; Mads Daugaard
Journal:  Cells       Date:  2020-03-28       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.